ArticleAnnals of hematology2025
Cerebrospinal fluid β2-microglobulin as a diagnostic biomarker in central nervous system lymphoma: a single-center retrospective analysis.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic changes in serum IL-6, TNF-Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective cohort study investigated the diagnostic performance of cerebrospinal fluid (CSF) β2-microglobulin (β2-M) in patients with central nervous system lymphoma (CNSL). Between January 2018 and August 2024, 1,349 hospitalized patients with CSF β2-M in our center were categorized into lymphoma, leukemia, solid tumor, and other disease cohorts, with additional stratification by central nervous system involvement. CSF β2-M concentrations were markedly elevated in CNSL relative to all other comparator groups (p < 0.001). A cut-off value of 1.85 mg/L discriminated CNSL from non-CNS-involved lymphoma with high diagnostic accuracy, yielding 85.7% sensitivity and 89.7% specificity. Longitudinal assessment further demonstrated that dynamic CSF β2-M trajectories correlated with therapeutic response and relapse risk. Collectively, these findings establish CSF β2-microglobulin as a reliable, accessible, and cost-effective diagnostic biomarker for CNSL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.